Headlands Technologies LLC Buys Shares of 94,250 Intellia Therapeutics, Inc. $NTLA

Headlands Technologies LLC purchased a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 94,250 shares of the company’s stock, valued at approximately $1,595,000. Headlands Technologies LLC owned 0.07% of Intellia Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. BlackRock Inc. purchased a new position in Intellia Therapeutics during the second quarter valued at approximately $260,721,000. ARK Investment Management LLC lifted its stake in Intellia Therapeutics by 19.2% in the 4th quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock worth $127,724,000 after purchasing an additional 2,288,146 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Intellia Therapeutics by 17.8% in the 4th quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock valued at $116,960,000 after purchasing an additional 1,965,181 shares during the period. State Street Corp boosted its holdings in Intellia Therapeutics by 29.1% in the 4th quarter. State Street Corp now owns 6,418,836 shares of the company’s stock valued at $57,705,000 after purchasing an additional 1,447,967 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Intellia Therapeutics by 4.1% during the 4th quarter. Geode Capital Management LLC now owns 2,696,187 shares of the company’s stock valued at $24,243,000 after purchasing an additional 107,333 shares in the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Stock Down 1.1%

NTLA opened at $12.73 on Tuesday. The stock has a market cap of $1.78 billion, a PE ratio of -3.79 and a beta of 1.81. Intellia Therapeutics, Inc. has a 52 week low of $7.95 and a 52 week high of $28.25. The business’s fifty day simple moving average is $13.19 and its 200 day simple moving average is $13.39.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.80). Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%.The firm had revenue of $7.66 million during the quarter, compared to analysts’ expectations of $12.98 million. During the same period in the prior year, the business earned ($0.98) EPS. The company’s revenue for the quarter was down 46.4% compared to the same quarter last year. As a group, equities analysts anticipate that Intellia Therapeutics, Inc. will post -3.21 earnings per share for the current year.

Insider Transactions at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,641 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total value of $44,315.98. Following the sale, the chief accounting officer directly owned 66,886 shares of the company’s stock, valued at $1,122,347.08. This trade represents a 3.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total value of $84,186.00. Following the transaction, the executive vice president owned 156,286 shares in the company, valued at approximately $2,813,148. This represents a 2.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 3.50% of the company’s stock.

Analyst Upgrades and Downgrades

NTLA has been the topic of several research analyst reports. Wall Street Zen cut shares of Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Friday, July 17th. Wolfe Research lowered Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 target price on the stock. in a research note on Wednesday, July 15th. Evercore upgraded Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 price target for the company in a research report on Friday, August 7th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $49.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, June 16th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $21.15.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.